Date	e: September 2 nd , 20	22			
You	r Name: Koichi Taira				
Mar	Manuscript Title: Efficacy of immunotherapy with chemotherapy as standard first-line of treatment				
aga	<u>inst advanced gastric can</u>	<u>icer</u>			
Mar	nuscript number (if known):	DMR-22-64	<u></u>		
In the relation to to the relation to the rela	In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u> . The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript without time limit. For all other items,				
the	time frame for disclosure is	Name all entities with whom you have this	Specifications/Comments (e.g., if payments were made to you or to your		
		relationship or indicate none (add rows as needed)	institution)		
		Time frame: Since the initial	planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	xNone			
		Time frame: past	36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	x None			
3	Royalties or licenses	x None			

Consulting fees

x

None

5	Payment or honoraria for	x None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events Payment for expert	x None	
0	testimony	x None	
	testimony		
7	Support for attending	x None	
,	meetings and/or travel		
8	Patents planned, issued or	x None	
	pending		
	'		
9	Participation on a Data	x None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	x None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	N	
11	Stock or stock options	x None	
12	Receipt of equipment,	x None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	x None	
	financial interests		
D I .	tt	adia adia and the control of the control of the	lauda a hau.
Plea	ase summarize the above co	inflict of interest in the fol	lowing box:
	lono		
'	lone.		

Date	e: September 2 nd , 20	22			
You	r Name: Akie Kimura				
Mar	Manuscript Title: Efficacy of immunotherapy with chemotherapy as standard first-line of treatment				
aga	<u>inst advanced gastric can</u>	<u>icer</u>			
Mar	nuscript number (if known):	DMR-22-64	<u></u>		
In the relation to the relatio	In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u> . The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript without time limit. For all other items,				
the	time frame for disclosure is	Name all entities with whom you have this relationship or indicate	Specifications/Comments (e.g., if payments were made to you or to your institution)		
		none (add rows as			
		needed)			
		Time frame: Since the initial	planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	x None			
	processing charges, etc.) No time limit for this item.				
	No time limit for this item.				
		Time frame: past	36 months		
2	Grants or contracts from	x None	30 months		
	any entity (if not indicated				
	in item #1 above).				
3	Royalties or licenses	x None			

Consulting fees

x

None

5	Payment or honoraria for	x None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events Payment for expert	x None	
0	testimony	x None	
	testimony		
7	Support for attending	x None	
,	meetings and/or travel		
8	Patents planned, issued or	x None	
	pending		
	'		
9	Participation on a Data	x None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	x None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	N	
11	Stock or stock options	x None	
12	Receipt of equipment,	x None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	x None	
	financial interests		
D I .	tt	adia adia and the control of the control of the	lauda a hau.
Plea	ase summarize the above co	inflict of interest in the fol	lowing box:
	lono		
'	lone.		

Date	e: September 2 nd , 20	22	
You	r Name: Akinobu Nakata		
Mar	nuscript Title: <u>Efficacy o</u>	f immunotherapy with	chemotherapy as standard first-line of treatment
aga	<u>inst advanced gastric can</u>	<u>icer</u>	
Mar	nuscript number (if known):	DMR-22-64	<u>_</u>
relar part to to to relar The mar to	ted to the content of your makes whose interests may be cansparency and does not not tionship/activity/interest, it following questions apply to the content only. author's relationships/activities epidemiology of hyperterestication, even if that medical em #1 below, report all supports the support all supports and the content of the content on the content of the content on the content of the	nanuscript. "Related" mean affected by the content of ecessarily indicate a bias. It is preferable that you do so the author's relationship wities/interests should be donsion, you should declare a tion is not mentioned in the	s/activities/interests as they relate to the <u>current</u> lefined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
the	time frame for disclosure is	the past 36 months.	
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	xNone	
		-:	26
2	Grants or contracts from	Time frame: past x None	36 months
۷	any entity (if not indicated in item #1 above).	NOTIE	
3	Royalties or licenses	x None	

None

Consulting fees

5	Payment or honoraria for	x None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events Payment for expert	x None	
0	testimony	x None	
	testimony		
7	Support for attending	x None	
,	meetings and/or travel		
8	Patents planned, issued or	x None	
	pending		
	'		
9	Participation on a Data	x None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	x None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	N	
11	Stock or stock options	x None	
12	Receipt of equipment,	x None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	x None	
	financial interests		
D I .	tt	adia adia and the control of the control of the	lauda a hau.
Plea	ase summarize the above co	inflict of interest in the fol	lowing box:
	lono		
'	lone.		

Date	e: September 2 nd , 202	22			
You	r Name: Fumio Tanaka				
Mar	Manuscript Title: Efficacy of immunotherapy with chemotherapy as standard first-line of treatment				
aga	<u>inst advanced gastric can</u>	<u>cer</u>			
Mar	nuscript number (if known):	DMR-22-64	<u></u>		
rela part to ti rela The <u>mar</u>	In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u> .				
to the med	ne epidemiology of hyperter lication, even if that medica em #1 below, report all supp	nsion, you should declare a tion is not mentioned in the port for the work reported	efined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive me manuscript. in this manuscript without time limit. For all other items,		
the	time frame for disclosure is	the past 36 months.			
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
		Time frame: Since the initial	planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	x None			
		Time frame: past	36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	xNone			
3	Royalties or licenses	x None			

None

Consulting fees

5	Payment or honoraria for	x None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events Payment for expert	x None	
0	testimony	x None	
	testimony		
7	Support for attending	x None	
,	meetings and/or travel		
8	Patents planned, issued or	x None	
	pending		
	'		
9	Participation on a Data	x None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	x None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	N	
11	Stock or stock options	x None	
12	Receipt of equipment,	x None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	x None	
	financial interests		
D I .	tt	adia adia and the control of the control of the	lauda a hau.
Plea	ase summarize the above co	inflict of interest in the fol	lowing box:
	lono		
'	lone.		

Date	e: September 2 nd , 20	22			
You	r Name: Yasuaki Nagami				
Mar	Manuscript Title: Efficacy of immunotherapy with chemotherapy as standard first-line of treatment				
aga	<u>inst advanced gastric can</u>	<u>icer</u>			
Mar	nuscript number (if known):	DMR-22-64	<u></u>		
In the relation to the relatio	In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u> . The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.				
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
		Time frame: Since the initial	planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	x None			
		- · •			
2	Grants or contracts from	Time frame: past x None	36 months		
2	any entity (if not indicated	x None			
	in item #1 above).				
3	Royalties or licenses	x None			
	•				

None

x

Consulting fees

5	Payment or honoraria for	x None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events Payment for expert	x None	
0	testimony	x None	
	testimony		
7	Support for attending	x None	
,	meetings and/or travel		
8	Patents planned, issued or	x None	
	pending		
	'		
9	Participation on a Data	x None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	x None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	N	
11	Stock or stock options	x None	
12	Receipt of equipment,	x None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	x None	
	financial interests		
D I .	tt	adia adia and the control of the control of the	lauda a hau.
Plea	ase summarize the above co	inflict of interest in the fol	lowing box:
	lono		
'	lone.		

Date	e: September 2 nd , 20	22	
You	r Name: Yasuhiro Fujiwara	1	
Mar	nuscript Title: <u>Efficacy o</u>	f immunotherapy with o	chemotherapy as standard first-line of treatment
aga	<u>inst advanced gastric can</u>	<u>icer</u>	
Mar	nuscript number (if known):	DMR-22-64	<u>_</u>
relate part to trelate	ted to the content of your miles whose interests may be ransparency and does not not too ship/activity/interest, it	nanuscript. "Related" mear affected by the content of ecessarily indicate a bias. I is preferable that you do s	
	following questions apply to uscript only.	o the author's relationship	s/activities/interests as they relate to the <u>current</u>
to th	•	nsion, you should declare a	efined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive manuscript.
	em #1 below, report all sup time frame for disclosure is	·	in this manuscript without time limit. For all other items,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	xNone	
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	x None	
	any entity (if not indicated in item #1 above).		

Royalties or licenses

Consulting fees

4

x__ None

None

5	Payment or honoraria for	x None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events Payment for expert	x None	
0	testimony	x None	
	testimony		
7	Support for attending	x None	
,	meetings and/or travel		
8	Patents planned, issued or	x None	
	pending		
	'		
9	Participation on a Data	x None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	x None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	N	
11	Stock or stock options	x None	
12	Receipt of equipment,	x None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	x None	
	financial interests		
D I .	tt	adia adia and the control of the control of the	lauda a hau.
Plea	ase summarize the above co	inflict of interest in the fol	lowing box:
	lono		
'	lone.		